Company intelligence / Profile preview
Cereno Scientific AB
Gothenburg, Swedencerenoscientific.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Phase 2
01
Overview
Lead candidate CS1 completed Phase IIa trial in PAH showing positive safety profile and compelling impact on exploratory clinical efficacy parameters. CS014 completed Phase I trial with top-line results expected in June 2025. CS585 is in preclinical development.
- Therapeutic areas
- PulmonologyCardiovascular
- Modalities
- HDACi (Histone deacetylase inhibitors)Prostacyclin receptor agonistsEpigenetic modulators
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →03
Partnerships
University of MichiganAbbottCTCPulmonary and Vascular Research Institute (PVRI)
Beyond the preview
Go deeper on Cereno Scientific AB.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cereno Scientific AB.